Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

Net Loss Per Share

6 Months Ended

Jun. 30, 2021

9.	Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:

	Six Months Ended June 30,
	2021			2020
Numerator:
Net loss	$	(5,273,247	)	$	(969,309	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		11,153,986			8,181,836
Net loss per share applicable to common stockholders – basic and diluted	$	(0.47	)	$	(0.12	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:

	Six Months Ended June 30,
	2021		2020
Options to purchase shares of stock		3,624,657		3,369,144
Warrants to purchase shares of stock		1,561,913		474,723
Total		5,186,570		3,843,867